| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/09/2002 | US6369041 In given dosage, optionally with other drug; treating cardiovascular disorders for example |
| 04/09/2002 | US6369039 Saturated solution; catheter |
| 04/09/2002 | US6369032 Method for treating allergies |
| 04/09/2002 | US6368855 MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expression |
| 04/09/2002 | US6368853 A nucleic acid encoding a polypeptide ligand; tyrosine kinase containing immunoglobulin and epidermal growth factor homolog domains; therapy and diagnosis for angiogenesis in wound healing, inflammation or tumors |
| 04/09/2002 | US6368842 An isolated nucleic acid; therapy for neuroblastomas in infant brains, uterus, lung, ovary adenocarcinomas and leukocytes |
| 04/09/2002 | US6368831 Treatment of hyperproliferative disorders |
| 04/09/2002 | US6368829 An isolated nucleic acid encoding a polypeptide for a tumor suppressor gene; diagnosis and therapy for diseases |
| 04/09/2002 | US6368826 A nucleic acid sequence encoding an insulin receptor substrate; therapy and diagnosis for tumors, cellular proliferative disorders, and cancer |
| 04/09/2002 | US6368824 Neuropeptide Y receptor Y5 and nucleic acid sequences |
| 04/09/2002 | US6368797 Determining the genotype at nucleotide 192 of a gene that is an indicator of an increased risk for alzheimer's disease by performing restriction enzyme digestion of an amplified product of the nucleic acid molecule |
| 04/09/2002 | US6368789 Screening methods to identify inhibitors of telomerase activity |
| 04/09/2002 | US6368787 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 04/09/2002 | US6368617 Dietary supplement |
| 04/09/2002 | US6368604 Non-pyrogenic derivatives of lipid A |
| 04/09/2002 | US6368597 Methods of treating diabetes |
| 04/04/2002 | WO2002027318A1 Methods and compositions for screening modulators of lipid kinases |
| 04/04/2002 | WO2002026998A2 Hydrolases |
| 04/04/2002 | WO2002026988A2 Human drug metabolizing enzymes |
| 04/04/2002 | WO2002026984A2 Potassium channel interactors and uses therefor |
| 04/04/2002 | WO2002026982A2 Secreted human proteins |
| 04/04/2002 | WO2002026954A2 Truncated phosphodiesterase-7 polypeptides |
| 04/04/2002 | WO2002026951A2 Oxidoreductases |
| 04/04/2002 | WO2002026950A2 Transferases |
| 04/04/2002 | WO2002026947A2 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 04/04/2002 | WO2002026929A2 Kini-3 motor protein and methods for its use |
| 04/04/2002 | WO2002026820A2 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 04/04/2002 | WO2002026805A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 04/04/2002 | WO2002026757A2 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 04/04/2002 | WO2002026736A1 A thiazolidinedione derivative and its use as antidiabetic |
| 04/04/2002 | WO2002026729A2 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| 04/04/2002 | WO2002026281A1 Coated medical devices |
| 04/04/2002 | WO2002026245A2 Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions |
| 04/04/2002 | WO2002026244A2 Compositions and methods of use for extracts of rutaceae plants |
| 04/04/2002 | WO2002026223A2 Catecholamine pharmaceutical compositions and methods |
| 04/04/2002 | WO2002026219A2 Otic microbial combinations for treatment of animals with ruptured tympanic membrane |
| 04/04/2002 | WO2002026217A2 Composition for the transdermal delivery of fentanyl |
| 04/04/2002 | WO2002026212A2 Microparticle compositions and methods for the manufacture thereof |
| 04/04/2002 | WO2002026209A2 Microparticles for delivery of the heterologous nucleic acids |
| 04/04/2002 | WO2002026193A2 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas |
| 04/04/2002 | WO2002026192A2 Viruses targeted to hypoxic cells and tissues |
| 04/04/2002 | WO2002026020A2 Tricyclic antidepressants and their analogues as long-acting local anesthetics and analgesics |
| 04/04/2002 | WO2002010339A3 Gene expression profile for kshv infection and methods for treating same |
| 04/04/2002 | WO2002004421A3 Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
| 04/04/2002 | WO2001096450A3 Fast cure film forming formulation |
| 04/04/2002 | WO2001089577A3 Conjugates of aminodrugs comprising an oxime bond |
| 04/04/2002 | WO2001088532A3 Improved assay techniques using nematode worms |
| 04/04/2002 | WO2001088106A3 Novel deoxyribonucleside kinase enzyme multi-substrate variants |
| 04/04/2002 | WO2001087376A8 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 04/04/2002 | WO2001087263A3 Delivery systems for treatment of vascular disease |
| 04/04/2002 | WO2001085980A3 Enzymatic assays for screening anti-cancer agents |
| 04/04/2002 | WO2001085694A3 Substituted diamide derivatives useful as motilin antagonists |
| 04/04/2002 | WO2001085142A8 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy |
| 04/04/2002 | WO2001073034A3 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 04/04/2002 | WO2001072846A3 Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof |
| 04/04/2002 | WO2001072839A3 Human g-protein coupled receptors |
| 04/04/2002 | WO2001072781A3 Human genes and expression products |
| 04/04/2002 | WO2001070205A3 Composition comprising paracetamol and niflumic acid |
| 04/04/2002 | WO2001066741A3 Kcnb: a novel potassium channel protein |
| 04/04/2002 | WO2001066098A3 Therapeutic uses of ppar mediators |
| 04/04/2002 | WO2001064896A3 Human enzyme molecules |
| 04/04/2002 | WO2001062792A3 Cancer treatment and prognosis involving hes-1 protein |
| 04/04/2002 | WO2001062778A3 Tumour-specific animal proteins |
| 04/04/2002 | WO2001060350A3 Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation |
| 04/04/2002 | WO2001055178A9 Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer |
| 04/04/2002 | WO2001053352A3 Sperm specific proteins |
| 04/04/2002 | WO2001049715A3 Methods and compositions for inhibiting neoplastic cell growth |
| 04/04/2002 | WO2001048231A3 Method of achieving persistent transgene expression |
| 04/04/2002 | WO2001047507A3 Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound |
| 04/04/2002 | WO2000072021A3 Cancer associated antigens and uses therefor |
| 04/04/2002 | WO2000070099A3 Differential gene expression in specific regions of the brain in neurodegenerative diseases |
| 04/04/2002 | US20020040484 Administering to cell a compound capable of modulating protein complex having a first protein which is delta -catenin interacting with a second protein which is FAK2 |
| 04/04/2002 | US20020040203 Method for transdermal or intradermal delivery of molecules |
| 04/04/2002 | US20020040149 EP4 receptor selective agonists in the treatment of osteoporosis |
| 04/04/2002 | US20020040132 Using one or more agonists and/or antagonists of the G protein coupled receptor GPR56 as test compounds in one or more appetite control test procedures, and selecting an active compound for use as an appetite control agent |
| 04/04/2002 | US20020040127 Nucleotide sequences which code tumor protein for use in diagnosis, prevention and treament of tumors |
| 04/04/2002 | US20020040063 Liquid formulation of metformin |
| 04/04/2002 | US20020040062 For upregulation of expression of a cell antigen without inducing shedding of said antigen from the cell |
| 04/04/2002 | US20020040061 Compounds such as 1-(3-(2-hydroxybenzoylamino)propyl)-2-pyrrolidinone; dosage forms of bioactive agents or drugs |
| 04/04/2002 | US20020040059 Controlling cancer by reducing its growth and improving response to therapy |
| 04/04/2002 | US20020040058 Oral administration of a preparation having a) long chain polyunsaturated fatty acids, and b) specified phospholipids, and c) compounds that factor in methionine metabolism, such as folate, B vitamins, magnesium and zinc |
| 04/04/2002 | US20020040056 Oxa acids and related compounds for treating skin conditions |
| 04/04/2002 | US20020040049 Administrating to a mammal a gastrointestinal lipase inhibitor, such as orlistat; reducing intensity of fullness, nausea, bloating or gastric distress following ingestion of fat rich meals or foods |
| 04/04/2002 | US20020040042 Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma |
| 04/04/2002 | US20020040039 Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
| 04/04/2002 | US20020040034 Administering to a human for treating allergic asthma while avoiding adverse side-effects associted with adminstration of nonsedating antihistamines, a descarboethoxyloratadine and a leukotriene inhibitor(a decongestant) |
| 04/04/2002 | US20020040024 A phenoxy substituted piperidine derivative, useful for treating or preventing histamine H3 receptor activity |
| 04/04/2002 | US20020040022 Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection |
| 04/04/2002 | US20020040015 Administering to the mammal an anti-angiogenesis factor and a photosensitizer to permit to localize in the chorodial neovasculature, irradiating the chorodial neovasculature with laser light |
| 04/04/2002 | US20020040011 Naphthoquinone compositions and uses thereof |
| 04/04/2002 | US20020040009 Novel ratA |
| 04/04/2002 | US20020040000 Human kcnq5 potassium channel, methods and compositions thereof |
| 04/04/2002 | US20020039997 Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection |
| 04/04/2002 | US20020039991 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 04/04/2002 | US20020039789 Method for production of neuroblasts |
| 04/04/2002 | US20020039756 Evaluation and classification of toxicity in humans; obtain samples, incubate with antibodies, detect bound complexes, increased concentration of bound complexes indicates toxicity in humans |
| 04/04/2002 | US20020039736 Reacting aliphatic aminonitrile with water in presence of solid alumina catalyst to form lactam |
| 04/04/2002 | US20020039724 Neural progenitor cell populations |
| 04/04/2002 | US20020039599 Calibration; administering antiseptic compound |
| 04/04/2002 | US20020039595 Capsule dosage units |